| Document |
Document Title |
|
WO/2022/258637A1 |
The invention relates to a radiotracer labelling precursor having the structure (I) comprising a first target vector (TV1), a second target vector (TV2), a labelling group (MG) for complexation or covalent binding of a radioisotope, a fi...
|
|
WO/2022/260483A1 |
The 18F-ApoPep-7 of chemical formula 1 according to the present invention, which is a derivative of 18F-ApoPep-1, has the manufacturing advantage of labeling the radioisotope F-18 with high radiochemical yield, radiochemical purify, and ...
|
|
WO/2022/261284A1 |
The present invention relates to a composition comprising solid crystalline, non-impact or non-detonation sensitive particles comprising 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), methods of preparing the crystalline form, an...
|
|
WO/2022/255915A1 |
The compounds of the invention are ASEM analogs with different ortho- and para-substitutions that can be labelled with 3H and/or 11C to be used as PET radiotracers capable of binding to α7-nAChR both in vitro and in vivo in a subject bo...
|
|
WO/2022/253785A2 |
The present invention relates to diagnosis and treatment of malignancies characterised by prostate-specific membrane antigen (PSMA) expression. The invention particularly relates to improved radiopharmaceuticals which selectively bind to...
|
|
WO/2022/251496A1 |
The present technology provides compounds, as well as compositions including such compounds, useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing e.g., a glypican-3 (GPC3) receptor and/or prostate specific mem...
|
|
WO/2022/246511A1 |
The present disclosure relates to cell penetrating anti-DNA antibodies conjugated to a payload and methods of delivering these antibody conjugates to the brain. Compositions comprising these antibody conjugates may be useful for detectin...
|
|
WO/2022/249089A1 |
Embodiments of the present invention provide compositions and methods for the treatment of cancer, in particular prostate cancer. According to certain embodiments, a method of treating cancer in a patient comprises administering to the p...
|
|
WO/2022/246510A1 |
The present disclosure relates to cell penetrating anti-DNA antibodies conjugated to a payload and methods of delivering these antibody conjugates to the brain. Compositions comprising these antibody conjugates may be useful for detectin...
|
|
WO/2022/246119A2 |
Disclosed herein are recombinant hosts comprising at least a first set of chromosomes and a second set of chromosomes, wherein at least one of the first set of chromosomes and the second set of chromosomes comprises a recombinant gene en...
|
|
WO/2022/245697A1 |
The disclosure provides compositions and methods for treating ocular neovascular diseases and conditions with HIFl-a Pathway Inhibitors and PFKFB3 Inhibitors. Exemplary ocular neovascular diseases and conditions treated using the provide...
|
|
WO/2022/245709A1 |
A process for delivering a radionuclide material is provided in which the radionuclide, such as holmium oxide, is coated on a glass microsphere. A coating, preferably a dipodal polysiloxane, is applied to the microsphere, which coating h...
|
|
WO/2022/246210A1 |
A targeted radiopharmaceutical of chemical Formula I, below, is disclosed wherein Q+3 is a trivalent radioactive isotope ion; M is a proton (H+), an ammonium ion or an alkali metal ion; "g" is a number that is 1 to about 12; the boxed mA...
|
|
WO/2022/245698A1 |
The disclosure provides methods and compositions for treating pancreatic and hepatic disease such as, pancreatic steatosis, pancreatic cancer, non-alcoholic fatty liver disease, non- alcoholic steatohepatitis, and hepatic cancer. The pro...
|
|
WO/2022/241811A1 |
A reagent for detecting axillary lymph node metastasis of breast cancer and the use thereof. Also disclosed is the use of 18F-Alfatide II, or a combination of 18F-Alfatide II and 18F-FDG in PET/CT detection of axillary lymph node metasta...
|
|
WO/2022/242892A1 |
The present invention relates to medical imaging, disease monitoring and theranostic approaches in neoplastic diseases of certain anti-CD38 single-domain antibodies (sdAb).
|
|
WO/2022/238553A1 |
Provided are novel SST receptor ligand compounds suitable for the imaging and/or the treatment of neuroendocrine tumors. These SST receptor ligand compounds are comprised of a SST binding motif, a silicon-fluoride acceptor group which ca...
|
|
WO/2022/237901A1 |
Provided herein are hyaluronic acid compositions comprising hyaluronic acid or modified hyaluronic acid or crosslinked hyaluronic acid and slowly resorbable particles, spheres and granules. Also provided are methods for augmenting soft t...
|
|
WO/2022/240817A1 |
Disclosed are methods of dopamine transporter (DaT) visualization in the brain of a subject (e.g., a subject suspected of suffering from Parkinson's disease, dementia with Lewy bodies, or Alzheimer's disease). The methods typically inclu...
|
|
WO/2022/235770A1 |
Embodiments of the present disclosure provide compositions comprising compounds useful to make radiotracers for positron emission tomography imaging, as well as methods for making and using these compositions.
|
|
WO/2022/232943A1 |
A chelator having the general structure (I) wherein each R1 is independently OH, NH or SH, and X is O, S, or NR3, wherein R3 is H or CH2C(=O)R1. Methods of making and using the chelator, metal chelates, and biological constructs for deli...
|
|
WO/2022/235676A1 |
Provided are compositions and methods for treating a solid or hematological cancer in a subject by administering an effective amount of a radioconjugated agent that targets one or more natural killer group 2, member D (NKG2D) ligands, al...
|
|
WO/2022/233768A1 |
A precursor designated as DAZTA5-PPA2 for PET/CT diagnosis and nuclear therapy|of SSR active lesions with radioisotopes 68Ga and 177Lu provides improved|affinity, specificity and imaging of small metastases.
|
|
WO/2022/234266A1 |
A method of distributing microparticles is provided, the method comprising: providing a plurality of microparticles at an insertion site in a medium; applying ultrasound to the insertion site that generates gas bubbles by cavitation at c...
|
|
WO/2022/232923A1 |
Monovalent antibodies such as nanobodies that are specific for galectin-1 are described. These monovalent antibodies are able to interfere with the activity of galectin-1, and thus may be used for the treatment of diseases associated wit...
|
|
WO/2022/231424A1 |
The invention relates to a targeting system for cancer comprising a radioisotope with improved therapeutic effect, the use thereof as a medicament, such as for cancers, to a dosage comprising the targeting system, the use thereof in ther...
|
|
WO/2022/230354A1 |
The purpose of the present invention is to provide a compound that can be suitably used in a fluorochrome or similar, a novel fluorochrome and kit for conveniently detecting cells, and a novel method for conveniently detecting cells or s...
|
|
WO/2022/230390A1 |
The storage method according to the present invention comprises storing an intermediate for a radiopharmaceutical composition in an acetate buffer. The intermediate is a complex between an anti-epidermal growth factor receptor antibody (...
|
|
WO/2022/232124A1 |
Disclosed are TATE derivatives having a linker between the TATE moiety and a macrocyclic radionuclide chelating moiety. Methods of synthesis and use are also disclosed. The compounds preferably exhibit a ratio of kidney:liver uptake by a...
|
|
WO/2022/232552A1 |
The present invention relates to compositions and methods for effective delivery of a therapeutic agent to a subject using a delivery vehicle comprising a domain to evade the subject's immune response. In some embodiments, the present in...
|
|
WO/2022/232121A1 |
Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.
|
|
WO/2022/231410A1 |
The invention relates to new radiopharmaceuticals that inhibit fibroblast activation protein (iFAP), which are based on the molecule ((R)-1-((6-hydrazinylnicotinoyl)-D-alanyl)pyrrolidin-2-yl)bo
ronic acid (HYNIC-iFAP), wherein the nitrog...
|
|
WO/2022/222978A1 |
A composition, comprising: (i) a conjugate the concentration of which is from approximately 0.1 mg/mL to approximately 50 mg/mL, the conjugate comprising a programmed death-ligand 1 (PD-L1) binding polypeptide and a chelator; (ii) a buff...
|
|
WO/2022/226326A1 |
Theranostic agents incorporating a chelating moiety that can chelate a radioactive metal isotope and a. PSMA-targeting moiety are disclosed herein. The theranostic agents, which can be used to treat and/or detect cancers associated with ...
|
|
WO/2022/225036A1 |
The present invention relates to a compound represented by formula (II), or a pharmaceutically acceptable salt or solvate of the compound. (In the formula, R1, R2, R3, R4 and R5 independently represent a hydrogen atom or an amino acid si...
|
|
WO/2022/225006A1 |
The present invention addresses the problem of providing anti-MUC5AC humanised antibodies labelled with radionuclides, said antibodies having excellent specificity for mucin subtype 5AC (MUC5AC) and excellent accumulation in tumours. The...
|
|
WO/2022/226299A1 |
The present disclosure relates to methods of treating a subject having cancer with an 225Ac-radiopharmaceutical, which comprises 225Ac chelated with a compound of Formula (I) wherein the compound binds to neurotensin receptor 1 (NTSR1) a...
|
|
WO/2022/225007A1 |
The present invention addresses the problem of providing an actinium-225-labeled anti-MUC5AC humanized antibody exhibiting excellent specificity to mucin subtype 5AC (MUC5AC), excellent clustering in tumors, and reduced kidney toxicity. ...
|
|
WO/2022/224980A1 |
The present invention addresses the problem of providing a complex that has higher stability than in the past without reducing drug efficacy. The complex of the present invention is a complex of an anti-CD20 antibody and a chelating agen...
|
|
WO/2022/218409A1 |
Disclosed in the present invention is a heptamethylcarbocyanine dye - crosslinked tetracyclic amine chelating agent conjugate, which comprises a cross-linking agent group L and a heptamethylcarbocyanine dye (HMCD) group that is coupled w...
|
|
WO/2022/219569A1 |
The present disclosure relates to folate receptor-targeted radiotherapeutic compounds and their use. The present disclosure relates to folate receptor-targeted radiolabeled imaging conjugates and their use. The present disclosure also re...
|
|
WO/2022/219075A2 |
The present disclosure pertains to polypeptides (in particular, polypeptides comprising Eph receptor domain(s), i.e., Eph receptor-derived polypeptides), nanovesicles (e.g., extracellular vesicles (EVs) and hybridosomes) comprising such ...
|
|
WO/2022/218640A1 |
The present invention relates to a method and a device for producing radionuclide-containing products having a substantially identical desired activity of the radioactivity at different application times, based on a specified calibration...
|
|
WO/2022/216084A1 |
The present invention relates to a nanoplatform for targeting macrophages and a composition for prevention or treatment of metastatic cancer. An embodiment of the present invention provides a nanoplatform for targeting macrophages, the n...
|
|
WO/2022/207906A1 |
The present disclosure relates to the field of diagnostic methods, and more particularly prostate cancer imaging. In particular, the disclosure relates to a radiopharmaceutical PSMA-binding compound for use in determining the presence an...
|
|
WO/2022/212876A1 |
The disclosure provides antibodies that specifically bind to a cleaved CDCP1 and antigenbinding fragments thereof and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, compr...
|
|
WO/2022/212958A1 |
Imaging and radiotherapeutic agents targeting fibroblast-activation protein-α (FAP-α) and/or prostate-specific membrane antigen (PSMA) and their use in imaging and treating FAP-α and/or PSMA-related diseases and disorders are disclosed.
|
|
WO/2022/212372A1 |
A composite wire uses a powder core to offer radiopaque enhancements without the drawbacks of a solid metal core. For example, composite wires may include highly radiopaque materials, such as tantalum and platinum, integrated into the wi...
|
|
WO/2022/211051A1 |
The present invention addresses the problem of providing a complex that has higher stability than in the past without reducing drug efficacy. The complex of the present invention is a complex of a chelating agent and an anti-EGFR antibod...
|
|
WO/2022/204417A1 |
Theranostic radiopharmaceutical compositions and methods for targeted infectious disease diagnosis and treatment are provided. The theranostic radiopharmaceutical compositions may include a conjugate of a nucleoside analog, a chelator, a...
|
